Experienced in Hairy Cell Leukemia (HCL)

Dr. David H. Vesole

Oncology | Hematology
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
Offers Telehealth
43 Years of Experience
Experienced in Hairy Cell Leukemia (HCL)
HackenSack Meridian health
HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, 
Hackensack, NJ 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Vesole is an Oncologist and a Hematologist in Hackensack, New Jersey. Dr. Vesole has been practicing medicine for over 43 years and is rated as an Experienced provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (MGUS), and Bone Marrow Transplant.

His clinical research consists of co-authoring 135 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Northwestern University Feinberg School Of Medicine
Residency
University of Iowa College of Medicine
Specialties
Oncology
Hematology
Licenses
Internal Medicine in NJ
Board Certifications
American Board Of Internal Medicine
Hospital Affiliations
Medstar Georgetown University Hospital
Hackensack University Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareFirst
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Clover Health
  • INSURANCE PLAN
  • MEDICARE MAPD
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Geisinger
  • HMO
  • POS
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

HMH - John Theurer Cancer Center - Hackensack
92 2nd Street, Hackensack, NJ 7601.
Call: 551-996-8297
Other Locations
MedStar Georgetown University Hospital
3800 Reservoir Road Northwest, Washington, DC 20007
Call: 551-996-8704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)
Enrollment Status: Withdrawn
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Belantamab
Study Phase: Phase 1
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Tandem Autologous Hematopoietic Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Drug
Study Drug: Bortezomib
Study Phase: Phase 3
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Randomized Phase III Trial of Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)
Enrollment Status: Active_not_recruiting
Publish Date: September 08, 2025
Intervention Type: Other, Drug
Study Drugs: Bortezomib, Carfilzomib, Dexamethasone, Lenalidomide
Study Phase: Phase 3
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase Ib-IIA Study of Combined Check Point Inhibition After Autologous Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: July 25, 2025
Intervention Type: Drug
Study Drugs: Ipilimumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drug: Belantamab Mafodotin
Study Phase: Phase 1
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma Relapsing on Current Therapy
Enrollment Status: Suspended
Publish Date: February 25, 2025
Intervention Type: Drug
Study Drugs: Selinexor, Carfilzomib, Pomalidomide, Daratumumab, Dexamethasone
Study Phase: Phase 2
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy
Enrollment Status: Completed
Publish Date: December 03, 2024
Intervention Type: Biological
Study Drug: Descartes 11
Study Phase: Phase 2
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Phase I Study of Single-agent and Combined Checkpoint Inhibition After Allogeneic Hematopoietic Stem Cell Transplantation in Patients at High Risk for Post-transplant Recurrence
Enrollment Status: Terminated
Publish Date: November 18, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 1
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
A Pilot Study of the Therapeutic Potential of Stem Cell Educator Therapy in Type 1 Diabetes
Enrollment Status: Completed
Publish Date: October 10, 2024
Intervention Type: Biological
Study Phase: Phase 1
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma
Enrollment Status: Terminated
Publish Date: July 10, 2024
Intervention Type: Drug
Study Phase: Phase 2
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
(PRO#11307) Phase III Randomized Study of Autologous Stem Cell Transplantation With High-dose Melphalan Versus High-dose Melphalan and Bortezomib in Patients With Multiple Myeloma 65 Year or Older
Enrollment Status: Terminated
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drugs: Melphalan, Bortezomib
Study Phase: Phase 2
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
PRO#1278: A Phase III Study of Fludarabine and Busulfan Versus Fludarabine, Busulfan and Low Dose Total Body Irradiation in Patients Receiving an Allogeneic Hematopoietic Stem Cell Transplant
Enrollment Status: Terminated
Publish Date: June 13, 2023
Intervention Type: Drug
Study Drugs: Fludarabine, Busulfan
Study Phase: Phase 3
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
A Phase I Open Label First in Human Dose Escalation of the Immunoproteasome Inhibitor M3258 as a Single Agent and Expansion Study of M3258 in Combination With Dexamethasone in Participants With Relapsed Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: March 24, 2023
Intervention Type: Drug
Study Drugs: M3258, Dexamethasone
Study Phase: Phase 1
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma Using a Conditioning Regimen of Fludarabine, Melphalan, and Bortezomib
Enrollment Status: Completed
Publish Date: May 25, 2022
Intervention Type: Drug
Study Phase: Phase 2
View 13 Less Clinical Trials

135 Total Publications

Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Real-world outcomes of patients with relapsed refractory multiple myeloma treated with commercial bispecific T-cell engager antibodies: a single center experience.
Journal: Leukemia & lymphoma
Published: December 02, 2025
View All 135 Publications
Similar Doctors
Elite in Hairy Cell Leukemia (HCL)
Dr. Jae H. Park
Hematology Oncology | Hematology | Oncology
Elite in Hairy Cell Leukemia (HCL)
Dr. Jae H. Park
Hematology Oncology | Hematology | Oncology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (9.8 miles away)
212-639-2000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jae Park is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Park is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Acute Lymphoblastic Leukemia (ALL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Elite in Hairy Cell Leukemia (HCL)
Dr. Omar I. Abdel-Wahab
Oncology
Elite in Hairy Cell Leukemia (HCL)
Dr. Omar I. Abdel-Wahab
Oncology

Memorial Hematology Lymphoma Group

1275 York Ave, 
New York, NY 
 (9.8 miles away)
212-639-2000
Languages Spoken:
English

Omar Abdel-Wahab is an Oncologist in New York, New York. Dr. Abdel-Wahab is rated as an Elite provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Reticulohistiocytoma, Hairy Cell Leukemia (HCL), Leukemia, Rosai-Dorfman Disease, and Bone Marrow Aspiration.

Douglas E. Gladstone
Elite in Hairy Cell Leukemia (HCL)
Dr. Douglas E. Gladstone
Oncology | Transplant Surgery
Elite in Hairy Cell Leukemia (HCL)
Dr. Douglas E. Gladstone
Oncology | Transplant Surgery

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
 (20.5 miles away)
516-734-8900
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Douglas Gladstone is a Transplant Surgeon in Lake Success, New York. Dr. Gladstone is rated as a Distinguished provider by MediFind in the treatment of Hairy Cell Leukemia (HCL). His top areas of expertise are Hairy Cell Leukemia (HCL), Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Bone Marrow Transplant, and Bone Marrow Aspiration.

VIEW MORE HAIRY CELL LEUKEMIA (HCL) DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Vesole's expertise for a condition
ConditionClose
  • Elite
  • Bone Marrow Transplant
    Dr. Vesole is
    Elite
    . Learn about Bone Marrow Transplant.
    See more Bone Marrow Transplant experts
  • Multiple Myeloma
    Dr. Vesole is
    Elite
    . Learn about Multiple Myeloma.
    See more Multiple Myeloma experts
  • Distinguished
  • Acute Myeloblastic Leukemia without Maturation
    Dr. Vesole is
    Distinguished
    . Learn about Acute Myeloblastic Leukemia without Maturation.
    See more Acute Myeloblastic Leukemia without Maturation experts
  • Acute Myeloid Leukemia (AML)
    Dr. Vesole is
    Distinguished
    . Learn about Acute Myeloid Leukemia (AML).
    See more Acute Myeloid Leukemia (AML) experts
  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
    Dr. Vesole is
    Distinguished
    . Learn about Monoclonal Gammopathy of Undetermined Significance (MGUS).
    See more Monoclonal Gammopathy of Undetermined Significance (MGUS) experts
  • Plasmacytoma
    Dr. Vesole is
    Distinguished
    . Learn about Plasmacytoma.
    See more Plasmacytoma experts
  • Relapsed Refractory Multiple Myeloma (RRMM)
    Dr. Vesole is
    Distinguished
    . Learn about Relapsed Refractory Multiple Myeloma (RRMM).
    See more Relapsed Refractory Multiple Myeloma (RRMM) experts
  • Schnitzler Syndrome
    Dr. Vesole is
    Distinguished
    . Learn about Schnitzler Syndrome.
    See more Schnitzler Syndrome experts
View All 7 Distinguished Conditions
  • Advanced
  • Acute Myeloblastic Leukemia with Maturation
    Dr. Vesole is
    Advanced
    . Learn about Acute Myeloblastic Leukemia with Maturation.
    See more Acute Myeloblastic Leukemia with Maturation experts
  • Childhood Acute Myeloid Leukemia
    Dr. Vesole is
    Advanced
    . Learn about Childhood Acute Myeloid Leukemia.
    See more Childhood Acute Myeloid Leukemia experts
  • Waldenstrom Macroglobulinemia
    Dr. Vesole is
    Advanced
    . Learn about Waldenstrom Macroglobulinemia.
    See more Waldenstrom Macroglobulinemia experts
  • Experienced
  • Acute Lymphoblastic Leukemia (ALL)
    Dr. Vesole is
    Experienced
    . Learn about Acute Lymphoblastic Leukemia (ALL).
    See more Acute Lymphoblastic Leukemia (ALL) experts
  • Acute Promyelocytic Leukemia
    Dr. Vesole is
    Experienced
    . Learn about Acute Promyelocytic Leukemia.
    See more Acute Promyelocytic Leukemia experts
  • Agranulocytosis
    Dr. Vesole is
    Experienced
    . Learn about Agranulocytosis.
    See more Agranulocytosis experts
  • Anemia
    Dr. Vesole is
    Experienced
    . Learn about Anemia.
    See more Anemia experts
  • Atypical Hemolytic Uremic Syndrome (aHUS)
    Dr. Vesole is
    Experienced
    . Learn about Atypical Hemolytic Uremic Syndrome (aHUS).
    See more Atypical Hemolytic Uremic Syndrome (aHUS) experts
  • B-Cell Lymphoma
    Dr. Vesole is
    Experienced
    . Learn about B-Cell Lymphoma.
    See more B-Cell Lymphoma experts
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment

    If you are experiencing a medical emergency, call 9-1-1.

    MediFind will contact the provider for your appointment request. You’ll receive status updates by email. Your provider or MediFind will reach out to you directly by phone or email to schedule your appointment or request additional information.

    Patient Details

    This information is for the patient who will be seen at the appointment.

      Close

      Returning patient? Use your address on file with the provider.

      Insurance Details

      Please provide information of the primary insurance holder as the practice may require this information to schedule.

      Insurance Provider *
      Insurance ProviderClose

      Appointments Details

      Let’s get more information about your appointment.

              0 / 1000
              0 / 1000
              By pressing the Submit button you are agreeing to MediFind’s Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.